Every 8-K that MetLife, Inc. (MET) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MET and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MET filings page.
MetLife, Inc. estimates variable investment income of at least $600 million pre-tax for the quarter ended September 30, 2026, compared with full-year 2026 guidance of approximately $1.6 billion pre-tax.
The estimate is preliminary and unaudited, and MetLife has not completed its financial closing procedures for the quarter. Actual results could differ materially; the preliminary figures are not a substitute for full financial statements prepared in accordance with U.S. GAAP.
MetLife, Inc. declared third quarter 2026 dividends on several series of preferred stock. The board approved a $0.31471411 quarterly dividend per share on the floating rate non-cumulative preferred stock, Series A, with a $25 liquidation preference. It also declared a $29.375 semi-annual dividend per share on the 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a $1,000 liquidation preference.
For the 5.625% non-cumulative preferred stock, Series E, MetLife declared a quarterly dividend of $351.5625 per share, or $0.3515625 per depositary share representing a 1/1,000th interest, and for the 4.75% non-cumulative preferred stock, Series F, a quarterly dividend of $296.875 per share, or $0.296875 per depositary share. These dividends are payable on September 15, 2026 to shareholders of record as of August 31, 2026.
MetLife, Inc. reported second quarter 2026 results and its board approved a new $3.0 billion common stock repurchase authorization.
Net income was $705 million, or $1.09 per share, up 6% per share from a year earlier. Adjusted earnings rose 15% to $1.6 billion, with adjusted EPS up 20% to $2.43. Premiums, fees and other revenues grew 7% to $13.7 billion, and net investment income increased 18% to $6.7 billion. Adjusted return on equity reached 17.0% for the second straight quarter. Book value per share was $38.59, with adjusted book value per share of $57.71.
All operating segments contributed, including Group Benefits adjusted earnings of $503 million (up 25%), Retirement and Income Solutions $377 million (up 2%), Asia $420 million (up 21%), Latin America $268 million (up 15%), and EMEA $108 million (up 8%). MetLife Investment Management reported adjusted earnings of $57 million and total assets under management of $748.1 billion, up 20%. The company returned over $1.1 billion to shareholders through share repurchases and common dividends in the quarter, while holding company cash and liquid assets totaled $3.4 billion.
MetLife, Inc. released preliminary figures for its variable investment income for the quarter ended June 30, 2026. The company currently estimates this income will be between $220 million and $270 million (pre-tax), which it contrasts with its full-year 2026 variable investment income guidance of approximately $1.6 billion (pre-tax).
Variable investment income reflects returns from private equity, real estate and other funds, as well as prepayment fees. MetLife emphasizes that these numbers are unaudited, based on information available to management as of the disclosure date, and may differ materially once full closing procedures are complete. The company cautions readers not to rely on these estimates as a substitute for full U.S. GAAP financial statements or to infer performance for future periods.
MetLife, Inc. shareholders held their annual meeting on June 16, 2026. Investors elected eleven directors to terms expiring at the 2027 annual meeting, with each nominee receiving a large majority of votes cast. Shareholders also ratified Deloitte & Touche LLP as MetLife’s independent auditor for 2026.
In addition, shareholders approved on an advisory (non-binding) basis the compensation paid to MetLife’s Named Executive Officers, as described in the 2026 proxy statement. Overall, the voting results indicate broad shareholder support for the company’s board, executive pay program, and external auditor.
MetLife, Inc. declared second quarter 2026 dividends on three series of preferred stock. The quarterly dividend is $0.31190376 per share on its floating rate non-cumulative preferred stock, Series A, which has a $25 per share liquidation preference.
Holders of the 5.625% non-cumulative preferred stock, Series E, will receive $351.5625 per share, equal to $0.3515625 per depositary share, based on a $25,000 per share liquidation preference. The 4.75% non-cumulative preferred stock, Series F, will pay $296.875 per share, or $0.296875 per depositary share, also on a $25,000 liquidation preference.
All these preferred dividends are payable on June 15, 2026, to shareholders of record as of May 29, 2026.
MetLife, Inc. reported strong first quarter 2026 results with broad-based growth. Net income rose 30% to $1.14 billion, or $1.74 per share, while adjusted earnings increased 18% to $1.59 billion, or $2.42 per share, driven by higher variable investment income, volume growth and favorable underwriting.
Premiums, fees and other revenues grew 5% to $14.3 billion, and net investment income increased 10% to $5.36 billion. Segments delivered double‑digit adjusted earnings growth in Group Benefits, Retirement and Income Solutions, Asia, EMEA and MetLife Investment Management. Return on equity reached 18.2%, with adjusted ROE at 17.0%. MetLife returned over $1.1 billion to shareholders via dividends and buybacks, while book value per share rose to $37.92 and adjusted book value per share to $57.41.
MetLife, Inc. is providing preliminary information on its variable investment income for the quarter ended March 31, 2026 ahead of its full quarterly results. The company estimates pre-tax variable investment income of $475 million to $525 million, compared with full-year 2026 guidance of approximately $1.6 billion pre-tax.
Variable investment income reflects results from private equity, real estate and other funds, as well as prepayment fees. The figures are unaudited, based on preliminary data, and may differ materially once financial closing procedures are complete. MetLife emphasizes that this information is not a substitute for U.S. GAAP financial statements and includes forward-looking statements subject to risk factors described in its SEC filings.
MetLife, Inc. filed a report confirming a previously announced first quarter 2026 dividend on its floating rate non-cumulative preferred stock, Series A. The dividend is $0.31501229 per share on shares with a $25 liquidation preference.
The company stated that the dividend will be payable on March 16, 2026, to shareholders of record as of Friday, February 27, 2026, because the normal record date of March 1, 2026 falls on a Sunday. The New York Stock Exchange had not yet set an ex-dividend date for the Series A preferred stock at the time of the announcement and is expected to set it following this confirmatory announcement.
MetLife, Inc. disclosed that on February 26, 2026 it issued $1,000,000,000 aggregate principal amount of 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056. The debentures are issued under a 2005 indenture with The Bank of New York Mellon Trust Company, N.A., as trustee, as supplemented on February 26, 2026.
The debentures were offered and sold under a shelf registration statement on Form S-3 and a February 24, 2026 prospectus supplement. MetLife entered into an underwriting agreement and a pricing agreement with major underwriters including Barclays Capital, BofA Securities, Citigroup, Goldman Sachs, Morgan Stanley and Wells Fargo Securities.
MetLife, Inc. reported that its Board of Directors increased its size from eleven to thirteen members and elected Daniel S. Glaser and Michelle R. Seitz as new directors effective February 24, 2026. Both were also appointed to multiple key Board committees and were determined to be independent directors.
Each new director will receive MetLife’s standard non-management director compensation, which currently consists of a $355,000 annual retainer, with $205,000 paid in common stock and $150,000 paid in cash. Retainers are pro-rated for partial-year service, with the first of four annual installments earned at the beginning of service.
MetLife, Inc. declared a series of preferred stock dividends for first quarter 2026. The company approved a semi-annual dividend of $29.375 per share on its 5.875% fixed-to-floating rate preferred stock, Series D, and quarterly dividends of $351.5625 per share on Series E and $296.875 per share on Series F, with holders of the related depositary shares receiving $0.3515625 and $0.296875 per share, respectively. MetLife also declared a quarterly dividend of $0.31501229 per share on its floating rate preferred stock, Series A, subject to final confirmation that it has met specified financial tests. All these dividends are payable on March 16, 2026, to shareholders of record as of February 27, 2026.
MetLife, Inc. furnished its quarterly and full-year 2025 earnings materials and provided an updated multi-year outlook. The company reported $3.6 billion of cash and liquid assets at its holding companies as of December 31, 2025, which is within its $3.0 billion to $4.0 billion target range, and plans to maintain this target in 2026.
MetLife states it returned approximately $4.4 billion to shareholders in 2025 and remains on track to generate about $25.0 billion of free cash flow over 2025–2029. Assuming a 10-year U.S. Treasury rate of 4.40% at December 31, 2026, S&P 500 annual returns of 5% and private equity returns of 9% in 2026, it estimates $1.6 billion of pre-tax variable investment income for 2026 and expects its two-year average free cash flow to adjusted earnings ratio to stay at 65%–75%. The company is maintaining near-term annual targets for adjusted return on equity of 15%–17%, double-digit adjusted earnings per share growth, and direct expense ratio targets of 12.1% for 2026 and 11.3% in 2029, while indicating it does not expect material liquidity deficiencies or covenant issues.
MetLife, Inc. has reorganized its business structure to highlight growth in asset management. In the fourth quarter of 2025, the company made MetLife Investment Management (MIM), its institutional asset management unit, a separate reportable segment, while MetLife Holdings is no longer a reportable segment and is now mainly included in Corporate & Other. Certain products formerly in MetLife Holdings have been reclassified into Group Benefits and Retirement and Income Solutions (RIS).
Following these changes, MetLife is now organized into six segments: Group Benefits, RIS, Asia, Latin America, Europe, the Middle East and Africa, and MIM, with additional results in Corporate & Other. Effective January 1, 2025, MetLife also amended agreements between MIM and MetLife entities so that MIM manages general account assets at current market fee rates, compared with 2024 terms. The company states that these updates did not change prior period consolidated net income or consolidated adjusted earnings and has provided a Historical Results Financial Supplement to help investors compare past periods under the new structure.
MetLife, Inc. reported that its institutional investment arm, MetLife Investment Management, has closed the acquisition of PineBridge Investments, LLC and certain related affiliates. This step makes PineBridge part of MetLife’s investment management platform as of December 30, 2025.
On the same date, MetLife also released a fact sheet showing the pro forma combined total assets under management for MetLife Investment Management and PineBridge, as if the acquisition had been completed on September 30, 2025. The news release and the pro forma combined AUM fact sheet are provided as exhibits, giving investors more detail on how the combined investment management businesses will look following the transaction.
MetLife, Inc. is providing an early look at certain 2025 results and its capital deployment plans. For the quarter ending December 31, 2025, it estimates variable investment income of approximately $385 million to $435 million (pre-tax), compared with a quarterly target of $425 million (pre-tax) based on full-year 2025 guidance of about $1.7 billion (pre-tax). For full year 2025, MetLife anticipates a 7.7% return on its private equity portfolio and plans to use an assumed 9% annual return in its 2026 outlook, contributing to an estimated $1.6 billion (pre-tax) of variable investment income in 2026.
The company expects to deploy about $4 billion of capital in 2025 to support organic growth and approximately $1 billion for merger and acquisition activity, including funding for the expected closing of its previously announced PineBridge Investments acquisition. Total common stock repurchases for 2025 are expected to be about $2.85 billion, including roughly $430 million in the fourth quarter, with a similar repurchase level anticipated in 2026. All figures are preliminary, unaudited and subject to change as year-end closing procedures are completed.
MetLife, Inc. filed a current report to disclose that, on December 1, 2025, it completed its previously announced transaction with Talcott Resolution Life Insurance Company to reinsure approximately $10 billion of U.S. retail variable annuity and rider reserves. This means a large block of MetLife’s variable annuity risk has been transferred to Talcott through a reinsurance arrangement.
The completion of this transaction is communicated under a Regulation FD disclosure, with further details provided in a related news release that is attached as an exhibit and incorporated by reference.
MetLife, Inc. declared quarterly dividends on its preferred stock, providing cash income to holders of its Series A, Series E and Series F securities. The Series A floating rate non-cumulative preferred stock will pay a quarterly dividend of $0.33489390 per share. The 5.625% non-cumulative preferred stock, Series E, will pay $351.5625 per share, or $0.3515625 per depositary share, each representing a 1/1,000th interest in a share. The 4.75% non-cumulative preferred stock, Series F, will pay $296.875 per share, or $0.296875 per depositary share, each representing a 1/1,000th interest in a share.
MetLife, Inc. furnished investor materials for the quarter ended September 30, 2025. The company provided an Earnings Release (Exhibit 99.1), a Quarterly Financial Supplement (Exhibit 99.2), a Total AUM Fact Sheet (Exhibit 99.3), and Supplemental Slides (Exhibit 99.4). These materials are furnished, not filed, and summarize quarterly results and assets under management.
MetLife, Inc. filed a Certificate of Elimination to remove its 3.850% Fixed Rate Reset Non‑Cumulative Preferred Stock, Series G, from its charter effective upon filing. The company previously redeemed, repurchased or otherwise reacquired all Series G shares.
The filing eliminates the Series G Certificate of Designations from the Amended and Restated Certificate of Incorporation. Shares formerly designated as Series G return to authorized but unissued preferred stock, par value $0.01 per share, without designation as to series.
MetLife, Inc. disclosed preliminary, unaudited estimates that its variable investment income for the quarter ended September 30, 2025 is expected to meet the company’s quarterly target of $425 million (pre-tax). This target is presented in the context of full-year 2025 guidance of approximately $1.7 billion (pre-tax) for variable investment income, which includes returns from private equity, real estate and other funds and prepayment fees. The company notes these figures are estimated and prepared in good faith on a basis consistent with prior periods but financial closing procedures are not complete and actual results could be materially different. These preliminary results are not substitutes for audited GAAP financial statements and are not necessarily indicative of future periods.
MetLife disclosed receipt of an unsolicited mini-tender offer from Potemkin Limited to buy up to 10,000 shares of MetLife common stock at $53.00 per share, which the filing states is about 34.42% below MetLife's closing price of $80.82 on September 12, 2025. The shares subject to the offer equal approximately 0.00002% of MetLife's outstanding common stock as of August 31, 2025. MetLife does not endorse the offer, is not associated with Potemkin, and on September 15, 2025 issued a news release advising shareholders not to tender and explaining that shareholders who already tendered may withdraw prior to the offer's scheduled expiration at 5:00 p.m. ET on October 7, 2025. The news release is attached as Exhibit 99.1 and incorporated by reference.
MetLife, Inc. filed an 8-K reporting a news release dated September 2, 2025, that it will redeem all outstanding shares of its 3.850% fixed rate reset non‑cumulative preferred stock, Series G, on September 15, 2025. The filing notes the cover page interactive data is provided in Inline XBRL and is signed by Timothy J. Ring, Senior Vice President and Secretary.
MetLife, Inc. announced dividend declarations for multiple preferred stock series. The company declared a quarterly dividend of $0.35263005 per share on its floating-rate Series A preferred (with a $25 liquidation preference). It also declared a semi-annual dividend of $29.375 per share on Series D (5.875% fixed-to-floating, $1,000 liquidation preference), a quarterly dividend equal to $351.5625 per share on Series E (5.625%, $25,000 liquidation preference; $0.3515625 per depositary share representing 1/1,000th), a quarterly dividend equal to $296.875 per share on Series F (4.75%, $25,000 liquidation preference; $0.296875 per depositary share representing 1/1,000th), and a semi-annual dividend of $19.250 per share on Series G (3.850%, $1,000 liquidation preference). The release is attached as Exhibit 99.1 and incorporated by reference.
MetLife, Inc. (NYSE: MET) filed a Form 8-K to report the results of its June 17, 2025 annual meeting of common shareholders. Three routine governance items were submitted and all received majority support.
- Board elections: Shareholders re-elected all eleven directors for terms expiring at the 2026 annual meeting. Support levels ranged from 97.8 % for Christian Mumenthaler to 94.4 % for Denise M. Morrison. Total broker non-votes on director items were 41.7 million.
- Auditor ratification: Deloitte & Touche LLP was re-appointed as independent auditor for 2025, receiving 558.7 million “For” votes (approx. 93 %), with 38.9 million against and 0.5 million abstentions.
- Say-on-Pay (advisory): Compensation for named executive officers was approved with 528.3 million “For” votes (approx. 95 %), 26.3 million against, and 1.9 million abstentions; 41.7 million broker non-votes applied.
No other business, financial results, or strategic transactions were disclosed. The filing is strictly limited to Item 5.07, indicating normal-course corporate governance actions rather than material operational developments.